Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid

doi 10.5772/intechopen.84933
Full Text
Abstract

Available in full text

Date
Authors
Publisher

IntechOpen

Related search

DPP-4 Inhibitor-Associated Bullous Pemphigoid in a Hemodialysis Patient

Internal Medicine
Internal MedicineMedicine
2020English

Higher Frequency of Dipeptidyl Peptidase IV Inhibitor Intake in Bullous Pemphigoid Patients Than in the French General Population

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2019English

Oral Diabetes Medications Other Than Dipeptidyl Peptidase-4 Inhibitors Are Not Associated With Bullous Pemphigoid: A Finnish Nationwide Case Control Study

Journal of the American Academy of Dermatology
Dermatology
2018English

Dipeptidyl Peptidase-4 (DPP-4; CD26)

Science-Business eXchange
2014English

Dipeptidyl Peptidase-Iv Inhibitors, a Risk Factor for Bullous Pemphigoid. Retrospective Multicenter Case-Control Study in France and Switzerland

Journal of the American Academy of Dermatology
Dermatology
2018English

Bullous Pemphigoid

2020English

Dipeptidyl Peptidase-4 Inhibitor Increases Vascular Leakage in Retina Through VE-cadherin Phosphorylation

Scientific Reports
Multidisciplinary
2016English

Bullous Pemphigoid Associated With Mantle Cell Lymphoma

Archives of Dermatology
2004English

Effect of Renal Insufficiency on the Pharmacokinetics of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor

Diabetes Care
Internal MedicineEndocrinologyAdvancedMetabolismSpecialized NursingDiabetes
2007English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy